Affinage

DEPDC1

DEP domain-containing protein 1A · UniProt Q5TB30

Length
811 aa
Mass
93.0 kDa
Annotated
2026-04-28
40 papers in source corpus 24 papers cited in narrative 24 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

DEPDC1 is a mitosis-associated nuclear and centrosomal protein that functions as a transcriptional co-regulator and signaling scaffold essential for cell proliferation, mitotic spindle integrity, and multiple oncogenic pathways. During mitosis, phosphorylation of DEPDC1 isoform a at Ser110 directs it to the centrosome, where it maintains centrosome integrity and bipolar spindle organization; its depletion causes multipolar spindles, mitotic arrest, and multinucleation (PMID:28602627, PMID:25902835). DEPDC1 interacts with the zinc-finger repressor ZNF224 to silence the NF-κB inhibitor A20, thereby sustaining NF-κB signaling, and forms a positive-feedback loop with FOXM1 to promote FOXM1 nuclear translocation and transcriptional activity, while also engaging E2F1 to drive G1-S progression (PMID:20587513, PMID:39004911, PMID:28634077). DEPDC1 additionally activates Wnt/β-catenin, JNK, RAS-ERK, and AKT/mTOR/HIF1α pathways across multiple tumor types, coupling proliferative signaling to drug resistance, glycolysis, and anti-tubulin drug-induced apoptosis via JNK-dependent MCL1 degradation (PMID:25064737, PMID:34268303, PMID:39068164).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2007 Medium

    Establishing that DEPDC1 is required for bladder cancer cell proliferation and localizes to the nucleus answered the basic question of whether this uncharacterized DEP-domain protein has oncogenic relevance.

    Evidence siRNA knockdown with growth inhibition readout; immunocytochemistry in bladder cancer cells

    PMID:17452976

    Open questions at the time
    • No molecular mechanism or interacting partner identified
    • Single cancer type tested
    • No mitotic role yet recognized
  2. 2010 High

    Identification of ZNF224 as a DEPDC1 binding partner and A20 as a transcriptional target established the first mechanism: DEPDC1 co-represses A20 to sustain NF-κB signaling, and disrupting this interaction triggers apoptosis.

    Evidence Reciprocal Co-IP; cell-permeable peptide disruption; in vitro and in vivo apoptosis rescue

    PMID:20587513

    Open questions at the time
    • How DEPDC1-ZNF224 is recruited to the A20 promoter is unknown
    • Whether this mechanism operates outside bladder cancer is untested
  3. 2014 High

    Cross-species genetic epistasis revealed that DEPDC1/LET-99 acts upstream of a heterotrimeric G-protein (GPA-11) to activate JNK, linking DEPDC1 to anti-tubulin drug-induced MCL1 degradation and apoptosis — the first non-transcriptional signaling axis for DEPDC1.

    Evidence C. elegans RNAi screen and epistasis; human cell JNK inhibition and MCL1 degradation assays

    PMID:25064737

    Open questions at the time
    • Direct biochemical interaction between DEPDC1 and G-protein subunits not shown in human cells
    • Whether DEPDC1's DEP domain mediates G-protein coupling is unresolved
  4. 2015 Medium

    Demonstrating that DEPDC1 expression peaks in mitosis and that its knockdown causes multipolar spindles and multinucleation established DEPDC1 as a bona fide mitotic regulator, not merely a proliferation-associated gene.

    Evidence Synchronized cell expression profiling; immunofluorescence of mitotic defects upon siRNA depletion

    PMID:25902835

    Open questions at the time
    • Mechanism by which DEPDC1 maintains spindle bipolarity unknown
    • No centrosomal localization yet determined
  5. 2017 High

    Mapping Ser110 phosphorylation as essential for centrosomal targeting of isoform a, and distinguishing cortical localization of isoform b, provided the first post-translational mechanism controlling DEPDC1 function and explained its role in centrosome integrity.

    Evidence Mass spectrometry; phospho-mutant rescue; immunofluorescence of isoform-specific localization

    PMID:28602627

    Open questions at the time
    • Kinase responsible for Ser110 phosphorylation not identified
    • Centrosomal substrates or effectors of DEPDC1 unknown
  6. 2017 Medium

    Showing DEPDC1 interacts with E2F1 and enhances its transcriptional activity broadened DEPDC1's role from NF-κB co-repressor to a more general transcriptional co-activator promoting G1-S transition.

    Evidence Co-IP; E2F reporter assay; cell cycle analysis; xenograft in prostate cancer

    PMID:28634077

    Open questions at the time
    • Whether DEPDC1 binds E2F1 directly or through a complex is unresolved
    • Genome-wide E2F1 target effects not mapped
  7. 2019 Medium

    DEPDC1 was connected to JNK-dependent chemoresistance in HCC and to CCL20/CCR6-mediated angiogenesis, revealing tissue-specific downstream effectors beyond NF-κB.

    Evidence JNK inhibitor reversal of DEPDC1 overexpression effects; CCL20/CCR6 siRNA rescue; in vitro angiogenesis

    PMID:31189746 PMID:31322256

    Open questions at the time
    • Direct binding to JNK pathway components not demonstrated
    • Whether CCL20 regulation is transcriptional or post-transcriptional unclear
  8. 2021 Medium

    DEPDC1 was placed downstream of ALPK2 kinase and upstream of Wnt/β-catenin-driven EMT, and its mRNA was shown to be stabilized by lncRNA linc-ROR via HNRNPK, establishing both upstream regulators and a key oncogenic effector pathway.

    Evidence Co-IP and rescue epistasis for ALPK2; lentiviral manipulation with in vivo metastasis imaging for Wnt axis; RIP for HNRNPK-mediated mRNA stabilization

    PMID:34210956 PMID:34268303 PMID:34741030

    Open questions at the time
    • Whether ALPK2 directly phosphorylates DEPDC1 is unknown
    • Mechanism by which DEPDC1 engages Wnt1/β-catenin not defined at protein level
  9. 2022 Medium

    Discovery of the DEPDC1-FOXM1 physical interaction and transcriptional repression of DEPDC1 by FOXO3a established transcription factor partnerships and a negative regulatory input, while also reinforcing Wnt/β-catenin as a shared downstream axis.

    Evidence Co-IP and colocalization for FOXM1; dual-luciferase promoter assay for FOXO3a; Wnt pathway reporter

    PMID:35795985 PMID:36072787

    Open questions at the time
    • FOXM1-DEPDC1 stoichiometry and domain requirements undefined
    • FOXO3a regulation not confirmed outside nephroblastoma
  10. 2024 High

    A FOXM1-DEPDC1 positive feedback loop was demonstrated: FOXM1 transcriptionally induces DEPDC1 via promoter binding, while DEPDC1 reciprocally promotes FOXM1 nuclear translocation and activity, providing the first self-reinforcing circuit for DEPDC1 in hepatocarcinogenesis.

    Evidence ChIP; reciprocal Co-IP; nuclear fractionation; siRNA rescue; luciferase reporter

    PMID:39004911

    Open questions at the time
    • Whether the feedback loop operates in non-hepatic cancers is unknown
    • Whether DEPDC1 directly chaperones FOXM1 or acts via an intermediary is unresolved
  11. 2024 Medium

    DEPDC1 was linked to metabolic reprogramming: it promotes glycolysis through AKT/mTOR/HIF1α and confers TKI resistance in renal cell carcinoma, expanding its role beyond proliferation to metabolic control.

    Evidence RNA-seq; non-targeted metabolomics; AKT/mTOR/HIF1α western blot; TKI resistance assays

    PMID:39068164

    Open questions at the time
    • Direct interaction with AKT or mTOR not shown
    • Metabolic targets of HIF1α downstream of DEPDC1 not defined
  12. 2025 Medium

    Translational and post-transcriptional regulation of DEPDC1 was further defined: METTL5-mediated 18S rRNA m6A methylation enhances DEPDC1 mRNA translation, and the DUXAP8 lncRNA stabilizes DEPDC1 mRNA via HNRNPF and miR-7-5p sponging.

    Evidence m6A modification and translation assays for METTL5; RIP for HNRNPF; miRNA sponge luciferase reporter

    PMID:39992478 PMID:40018408

    Open questions at the time
    • Whether METTL5-mediated regulation is DEPDC1-selective or part of global translational control unknown
    • Relative contribution of miRNA sponging versus HNRNPF-mediated stabilization not quantified

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key mechanistic questions remain: the kinase phosphorylating Ser110, the structural basis of DEPDC1's DEP domain interactions, and whether DEPDC1 possesses intrinsic enzymatic activity or functions solely as a scaffold/co-regulator.
  • No crystal or cryo-EM structure available
  • DEP domain function not dissected biochemically
  • No unbiased proteomics of DEPDC1 interactome reported
  • Whether DEPDC1 has catalytic activity (e.g. GAP activity) is untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0098772 molecular function regulator activity 4 GO:0060090 molecular adaptor activity 3
Localization
GO:0005634 nucleus 3 GO:0005856 cytoskeleton 2 GO:0005815 microtubule organizing center 1
Pathway
R-HSA-162582 Signal Transduction 10 R-HSA-1643685 Disease 4 R-HSA-1640170 Cell Cycle 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-5357801 Programmed Cell Death 2
Partners
ALPK2E2F1FOXM1KIF20AKIF4AS100A16ZNF224

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 DEPDC1 protein localizes to the nucleus of bladder cancer cells, and siRNA-mediated suppression of DEPDC1 significantly inhibits growth of bladder cancer cells, establishing a role in tumor cell proliferation. Immunocytochemical staining for subcellular localization; siRNA knockdown with cell growth readout Oncogene Medium 17452976
2010 DEPDC1 physically interacts with the zinc finger transcription factor ZNF224 (a transcriptional repressor) in bladder cancer cells; this complex suppresses transcription of A20, an NF-κB inhibitor. Disrupting the DEPDC1-ZNF224 interaction with a cell-permeable peptide triggers A20 transcriptional activation and induces apoptosis in vitro and in vivo. Co-immunoprecipitation; immunocytochemistry colocalization; cell-permeable peptide inhibitor; in vitro and in vivo apoptosis assays Cancer research High 20587513
2014 In C. elegans, the DEPDC1 ortholog LET-99 acts upstream of the heterotrimeric G-protein alpha subunit GPA-11 to control activation of the stress kinase JNK-1 in the anti-tubulin drug-induced apoptosis pathway. Human DEPDC1 similarly promotes vincristine-induced cell death via JNK-dependent degradation of the BCL-2 family protein MCL1. In vivo C. elegans RNAi screen; genetic epistasis; human cell-line JNK inhibition and MCL1 degradation assays Nature cell biology High 25064737
2015 DEPDC1 is highly expressed in mitotic phase cells; siRNA-mediated knockdown causes mitotic arrest, multipolar spindle structures, and multiple nuclei, accompanied by upregulation of A20 and cell cycle genes CCNB1 and CCNB2, establishing a pivotal role in mitotic progression. Synchronized cell expression analysis; immunofluorescence; siRNA knockdown with mitotic phenotype readout BMB reports Medium 25902835
2017 DEPDC1 isoform a localizes to the centrosome in metaphase (while isoform b localizes to the cell cortex during mitosis); phosphorylation of DEPDC1 at Ser110 is required for centrosomal localization of isoform a and for maintenance of centrosome integrity and bipolar spindle organization. Non-phosphorylatable mutants of DEPDC1a fail to rescue centrosome disruption caused by endogenous DEPDC1 depletion. Mass spectrometry identification of phospho-Ser110; biochemical phosphorylation assays; immunofluorescence localization; site-directed mutagenesis rescue experiments Experimental cell research High 28602627
2017 DEPDC1 interacts with the transcription factor E2F1 and increases its transcriptional activity, promoting G1-S phase cell cycle transition and tumor growth in prostate cancer cells. Co-immunoprecipitation; cell cycle analysis; in vivo xenograft model; E2F reporter assay Biochemical and biophysical research communications Medium 28634077
2017 DEPDC1 depletion in nasopharyngeal carcinoma cells causes upregulation of A20 and downregulation of multiple NF-κB downstream target genes (c-Myc, BCL2, CCND1, CCNB1, CCNB2, MMP2, MMP9, ICAM1, vimentin, Twist1), as well as mitotic defects including multipolar spindles and multiple nuclei, indicating DEPDC1 maintains NF-κB signaling and mitotic integrity. siRNA knockdown; immunofluorescence; RT-PCR and western blot of NF-κB targets; in vivo xenograft Oncotarget Medium 28969015
2019 DEPDC1 knockdown in hepatocellular carcinoma significantly inhibits CCL20 and CCR6 expression; DEPDC1 promotes HCC cell proliferation, invasion, and angiogenesis through the CCL20/CCR6 signaling pathway, as shown by reversal of DEPDC1 overexpression effects upon CCL20 or CCR6 knockdown. DNA microarray; RT-qPCR; western blot; siRNA rescue experiments; in vitro angiogenesis assay Oncology reports Medium 31322256
2019 DEPDC1 promotes HCC cell viability and chemotherapy resistance through the JNK signaling pathway, as demonstrated by use of the JNK-specific inhibitor SP600125 reversing DEPDC1-mediated effects. JNK pharmacological inhibition; CCK8 cell viability; colony formation; in vivo xenograft Bioscience reports Medium 31189746
2020 DEPDC1 upregulates RAS expression and thereby enhances ERK1/2 activity, inhibiting autophagy in lung adenocarcinoma cells. Knockdown or overexpression of DEPDC1 reciprocally modulates RAS-ERK1/2 signaling and autophagy markers. Western blot upon DEPDC1 knockdown and overexpression; RAS-ERK1/2 pathway analysis; autophagy marker analysis Journal of cellular and molecular medicine Medium 33021072
2021 Linc-ROR acts as a competing endogenous RNA to stabilize DEPDC1 mRNA and regulates DEPDC1 mRNA stability by binding HNRNPK, thereby promoting HCC progression and angiogenesis through DEPDC1 upregulation. RNA-binding protein immunoprecipitation; miRNA sponge assay; DEPDC1 mRNA stability assays; functional proliferation and angiogenesis assays Cell death & disease Medium 34741030
2021 DEPDC1 promotes HCC migration and invasion via Wnt/β-catenin signaling and epithelial-mesenchymal transition, with DEPDC1 expression modulating Wnt1, β-catenin, vimentin, and E-cadherin levels. Lentiviral DEPDC1 manipulation; western blot; in vivo bioluminescence imaging of metastasis; wound healing and transwell assays Frontiers in cell and developmental biology Medium 34268303
2021 ALPK2 kinase directly interacts with DEPDC1A and acts upstream of it; overexpression of DEPDC1A rescues the inhibitory effects of ALPK2 knockdown on bladder cancer cell proliferation, apoptosis, and migration, placing DEPDC1 downstream of ALPK2 in bladder cancer. Co-immunoprecipitation; siRNA knockdown; rescue overexpression experiments; in vivo xenograft Cell death & disease Medium 34210956
2022 FOXO3a binds to the DEPDC1 promoter and represses its transcription. DEPDC1 in turn promotes nephroblastoma cell proliferation, invasion, and migration via Wnt/β-catenin signaling (modulating p-GSK-3β, Wnt3a, and β-catenin), and DEPDC1 overexpression reverses FOXO3a-mediated inhibition. Dual-luciferase reporter assay; immunoprecipitation; siRNA/overexpression; western blot of Wnt/β-catenin components Molecular medicine reports Medium 35795985
2022 DEPDC1 physically interacts with FOXM1 in oral squamous cell carcinoma; this interaction facilitates Wnt/β-catenin signal transduction and promotes β-catenin nuclear localization. Co-immunoprecipitation; immunofluorescence colocalization; Wnt/β-catenin pathway reporter analysis Frontiers in oncology Medium 36072787
2022 SIRT1 binds to the miR-20b-3p promoter to suppress miR-20b-3p expression; miR-20b-3p directly targets DEPDC1 to suppress its expression, and this SIRT1/miR-20b-3p/DEPDC1 axis mediates oxaliplatin resistance in colorectal cancer cells. Chromatin immunoprecipitation or promoter binding assay; luciferase reporter for miRNA-target validation; siRNA knockdown; cell viability and resistance assays Cell biology international Medium 36200529
2023 DEPDC1 interacts with KIF4A (confirmed by co-immunoprecipitation); DEPDC1 depletion activates the Hippo signaling pathway (increased p-LATS1 and p-YAP), and KIF4A upregulation reverses these effects and the associated suppression of osteosarcoma malignant behaviors. Co-immunoprecipitation; western blot of Hippo pathway components; siRNA and overexpression rescue experiments Journal of orthopaedic surgery and research Medium 36849972
2023 S100A16 directly binds DEPDC1 (confirmed by Co-IP); S100A16 promotes nephroblastoma progression and angiogenesis through PI3K/Akt/mTOR signaling, and DEPDC1 overexpression partially reverses the inhibitory effect of S100A16 knockdown. Co-immunoprecipitation; western blot of PI3K/Akt/mTOR components; siRNA and overexpression rescue; tube formation assay Polish journal of pathology Low 37955537
2024 FOXM1 transcriptionally induces DEPDC1 expression by binding to its promoter; in turn, DEPDC1 physically interacts with FOXM1, promotes its nuclear translocation, and reinforces FOXM1 transcriptional activity, forming a positive feedback loop that drives hepatocarcinogenesis. Chromatin immunoprecipitation; Co-IP; nuclear fractionation; siRNA rescue; luciferase reporter Cancer science High 39004911
2024 DEPDC1 promotes glycolysis and malignant progression in renal cell carcinoma via the AKT/mTOR/HIF1α pathway; DEPDC1 knockdown reverses TKI resistance, as supported by RNA-seq and non-targeted metabolomics combined with protein-level pathway analysis. RNA-seq; non-targeted metabolomics; western blot of AKT/mTOR/HIF1α pathway; siRNA knockdown; TKI resistance assays Cell death & disease Medium 39068164
2024 DEPDC1 interacts with TTK kinase (predicted by STRING and supported by binding assays) and upregulates RAS expression through TTK, enhancing ERK activity and thereby regulating autophagy-dependent glycolysis in osteosarcoma cells. Western blot; extracellular acidification rate; glucose uptake/lactate assays; siRNA knockdown; STRING-predicted interaction Anti-cancer drugs Low 39016842
2025 METTL5-mediated m6A methylation of 18S rRNA enhances translation of DEPDC1 mRNA, promoting lung squamous cell carcinoma tumorigenesis; METTL5 knockdown markedly inhibits DEPDC1 protein levels and tumor cell proliferation and migration. m6A modification assays; METTL5 knockdown/overexpression; translation assays; in vitro and in vivo functional assays Frontiers in oncology Medium 40018408
2025 DUXAP8 lncRNA (induced by YY1) stabilizes DEPDC1 mRNA through HNRNPF binding and also acts as a miR-7-5p sponge to prevent miR-7-5p-mediated DEPDC1 suppression, thereby promoting HCC proliferation and metastasis. RNA immunoprecipitation; luciferase reporter assay; RIP for HNRNPF; miRNA sponge assay Clinical and experimental medicine Medium 39992478
2025 DEPDC1 interacts with KIF20A (confirmed by co-immunoprecipitation); DEPDC1 overexpression promotes liposarcoma cell proliferation, migration, and invasion through activation of the PI3K/AKT/mTOR signaling pathway, and KIF20A deletion partially mitigates these effects. Co-immunoprecipitation; western blot of PI3K/AKT/mTOR; siRNA/overexpression; in vitro proliferation/migration assays Frontiers in endocrinology Low 40600015

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 93 17452976
2010 Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. Cancer research 86 20587513
2016 Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer letters 58 27984115
2018 DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer letters 51 30419349
2015 DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB reports 45 25902835
2017 DEPDC1 promotes cell proliferation and tumor growth via activation of E2F signaling in prostate cancer. Biochemical and biophysical research communications 44 28634077
2014 DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nature cell biology 41 25064737
2017 DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma. Oncotarget 37 28969015
2019 DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncology reports 31 31322256
2021 Artemisia argyi Essential Oil Inhibits Hepatocellular Carcinoma Metastasis via Suppression of DEPDC1 Dependent Wnt/β-Catenin Signaling Pathway. Frontiers in cell and developmental biology 27 34268303
2023 Glycolysis-Related Gene Analyses Indicate That DEPDC1 Promotes the Malignant Progression of Oral Squamous Cell Carcinoma via the WNT/β-Catenin Signaling Pathway. International journal of molecular sciences 25 36768316
2021 Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression. Cell death & disease 22 34741030
2019 DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma. Bioscience reports 20 31189746
2024 DEPDC1 as a metabolic target regulates glycolysis in renal cell carcinoma through AKT/mTOR/HIF1α pathway. Cell death & disease 19 39068164
2017 Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. Journal of neuro-oncology 19 28555424
2020 DEPDC1 up-regulates RAS expression to inhibit autophagy in lung adenocarcinoma cells. Journal of cellular and molecular medicine 18 33021072
2022 SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA-20b-3p/DEPDC1 axis. Cell biology international 15 36200529
2020 NNK-mediated upregulation of DEPDC1 stimulates the progression of oral squamous cell carcinoma by inhibiting CYP27B1 expression. American journal of cancer research 15 32642287
2017 Phosphorylation of DEPDC1 at Ser110 is required to maintain centrosome organization during mitosis. Experimental cell research 14 28602627
2022 Long non-coding RNA DEPDC1-AS1 promotes proliferation and migration of human gastric cancer cells HGC-27 via the human antigen R-F11R pathway. The Journal of international medical research 13 35466755
2024 Exosomal miR-130b-3p suppresses metastasis of non-small cell lung cancer cells by targeting DEPDC1 via TGF-β signaling pathway. International journal of biological macromolecules 12 38960258
2022 DEPDC1 as a crucial factor in the progression of human osteosarcoma. Cancer medicine 12 36479633
2021 ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A. Cell death & disease 12 34210956
2017 Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. Oncoimmunology 12 28919988
2022 miR-455-5p enhances 5-fluorouracil sensitivity in colorectal cancer cells by targeting PIK3R1 and DEPDC1. Open medicine (Warsaw, Poland) 11 35582195
2022 Silencing eL31 suppresses the progression of colorectal cancer via targeting DEPDC1. Journal of translational medicine 11 36309731
2023 DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway. Journal of orthopaedic surgery and research 10 36849972
2022 FOXO3a‑modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt/β‑catenin signaling pathway. Molecular medicine reports 9 35795985
2022 FOXM1 is regulated by DEPDC1 to facilitate development and metastasis of oral squamous cell carcinoma. Frontiers in oncology 7 36072787
2024 FOXM1/DEPDC1 feedback loop promotes hepatocarcinogenesis and represents promising targets for cancer therapy. Cancer science 6 39004911
2023 S100A16 cooperates with DEPDC1 to promote the progression and angiogenesis of nephroblastoma through PI3K/Akt/mTOR pathway. Polish journal of pathology : official journal of the Polish Society of Pathologists 6 37955537
2021 [DEPDC1 is Highly Expressed in Lung Adenocarcinoma and Promotes Tumor Cell Proliferation]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 5 34134185
2024 Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer. PloS one 3 38564630
2025 YY1-mediated DUXAP8 facilitates HCC progression via modulating DEPDC1 expression. Clinical and experimental medicine 2 39992478
2025 The human 18S rRNA m6A methyltransferase METTL5 promotes tumorigenesis via DEPDC1 in lung squamous cell carcinoma. Frontiers in oncology 2 40018408
2024 DEPDC1 affects autophagy-dependent glycolysis levels in human osteosarcoma cells by modulating RAS/ERK signaling through TTK. Anti-cancer drugs 2 39016842
2024 Roles of DEPDC1 in various types of cancer (Review). Oncology letters 2 39296974
2026 TCF7L2/DEPDC1 axis contributes to tumor progression by promoting cell proliferation, aerobic glycolysis, and immunosuppression in pancreatic cancer. Clinical and experimental medicine 0 41851532
2025 DEPDC1 facilitated malignant phenotypes and disease progression of liposarcoma by modulating KIF20A. Frontiers in endocrinology 0 40600015
2025 LncRNA DEPDC1-AS1 drives the progression of endometrial carcinoma by regulating miR-508-3p. Discover oncology 0 41003831